Paper · 35501832
Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
Weickhardt AJ and 8 others. BMC Cancer, 2022. Cited by 19 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer. Papers, record 35501832. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35501832
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptor, Fibroblast Growth Factor, Type 3 | Major topic |
| Urinary Bladder Neoplasms | Major topic |
| Cell Line, Tumor | |
| Female | |
| Humans | |
| Male | |
| Microtubule-Associated Proteins | |
| Protein Kinase Inhibitors | |
| Pyrazoles | |
| Pyrimidines | |
| Pyrroles | |
| Receptor, ErbB-3 |
Source PubMed
Grants4
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Australian Postgraduate award | La Trobe University | PubMed | ||
| Australian Postgraduate award | La Trobe University | PubMed | ||
| Australian Postgraduate award | La Trobe University | PubMed | ||
| 1046092 | National Health and Medical Research Council | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28,601,352 | Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. | Eur Urol | 2017 | https://conductscience.org/library/papers/28601352 | PubMed |
| 2 | 11,745,189 | The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas. | Cancer | 2001 | https://conductscience.org/library/papers/11745189 | PubMed |
| 3 | 10,471,491 | Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. | Nat Genet | 1999 | https://conductscience.org/library/papers/10471491 | PubMed |
| 4 | 17,668,422 | FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. | J Pathol | 2007 | https://conductscience.org/library/papers/17668422 | PubMed |
| 5 | 24,846,059 | FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. | Cancer Med | 2014 | https://conductscience.org/library/papers/24846059 | PubMed |
| 6 | 31,850,207 | Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. | Front Oncol | 2019 | https://conductscience.org/library/papers/31850207 | PubMed |
| 7 | 34,551,969 | Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study. | Cancer Discov | 2022 | https://conductscience.org/library/papers/34551969 | PubMed |
| 8 | 22,448,344 | EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. | Cancer Discov | 2012 | https://conductscience.org/library/papers/22448344 | PubMed |
| 9 | 24,909,170 | Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. | Oncogene | 2015 | https://conductscience.org/library/papers/24909170 | PubMed |
| 10 | 29,848,605 | Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. | Cancer Discov | 2018 | https://conductscience.org/library/papers/29848605 | PubMed |
1 to 10 of 41
See all 41 referencesCited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,724,638 | Treating T24 cells with erianin restores gefitinib drug sensitivity by regulating MYLK to inhibit EGFR and EMT processes. | Am J Cancer Res | 2026 | https://conductscience.org/library/papers/42724638 | PubMed |
| 41,820,966 | HER3 beyond the canonical paradigm: a versatile signaling hub in oncogenesis and therapeutic resistance. | J Transl Med | 2026 | https://conductscience.org/library/papers/41820966 | PubMed |
| 41,409,251 | Overcoming resistance in advanced urothelial carcinoma: mechanisms of escape from antibody-drug conjugates and FGFR3 inhibition. | Front Oncol | 2025 | https://conductscience.org/library/papers/41409251 | PubMed |
| 40,227,644 | From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment of Non-Muscle Invasive Bladder Cancer. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40227644 | PubMed |
| 39,161,208 | FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies. | Cancer Commun (Lond) | 2024 | https://conductscience.org/library/papers/39161208 | PubMed |
| 39,031,286 | The roles of FGFR3 and c-MYC in urothelial bladder cancer. | Discov Oncol | 2024 | https://conductscience.org/library/papers/39031286 | PubMed |
| 39,023,557 | Conundrum of 3N: nasopharyngeal nonkeratinizing non-viral carcinoma-reappraisal of fusions and report of two consecutive cases with unusual molecular findings. | Virchows Arch | 2025 | https://conductscience.org/library/papers/39023557 | PubMed |
| 38,864,084 | Do Fibroblast Growth Factor Receptor (FGFR) 2 and 3 Proteins Play a Role in Prognosis of Invasive Urothelial Bladder Carcinoma? | Iran J Pathol | 2024 | https://conductscience.org/library/papers/38864084 | PubMed |
| 38,675,715 | Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma. | Molecules | 2024 | https://conductscience.org/library/papers/38675715 | PubMed |
| 38,197,196 | TACC3: a multi-functional protein promoting cancer cell survival and aggressiveness. | Cell Cycle | 2023 | https://conductscience.org/library/papers/38197196 | PubMed |
1 to 10 of 15
See all 15 cited byGenes15
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| BAIAP2L1 | 55,971 | PubTator's text mining | https://conductscience.org/library/genes/55971 | NCBI Gene |
| EGFR | 1,956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| EIF2AK3 | 9,451 | PubTator's text mining | https://conductscience.org/library/genes/9451 | NCBI Gene |
| ERBB2 | 2,064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| ERBB3 | 2,065 | PubTator's text mining | https://conductscience.org/library/genes/2065 | NCBI Gene |
| FGFR2 | 2,263 | PubTator's text mining | https://conductscience.org/library/genes/2263 | NCBI Gene |
| FGFR3 | 2,261 | PubTator's text mining | https://conductscience.org/library/genes/2261 | NCBI Gene |
| MAP2K7 | 5,609 | PubTator's text mining | https://conductscience.org/library/genes/5609 | NCBI Gene |
| MAPK1 | 5,594 | PubTator's text mining | https://conductscience.org/library/genes/5594 | NCBI Gene |
1 to 10 of 15
See all 15 genesDrugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35501832
GET https://conductscience.org/api/papers/v1/35501832/references?page=2